분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2011-10-04 16:35:48 , Hit : 2325
 Treatment of Common Virus Can Reduce Tumour Growth, Study Suggests

Science News
ScienceDaily (Sep. 27, 2011) — Researchers at Karolinska Institutet in Sweden have demonstrated for the first time that it is possible to inhibit the growth of brain tumours by treating the common Cytomegalovirus (CMV). The virus, which is found in a wide range of tumour types, offers a possible route towards controlling tumour growth and reducing the size of the tumour as a complement to conventional cytotoxin-based therapies.

The CMV is a common virus that is found in 70-75 per cent of the adult population. Normally it is dormant and goes unnoticed, but when a cancer develops in the body, the virus seems to control many of the mechanisms in the cancer cells. Brain tumours, breast cancer, colon cancer and prostate cancer are some of the cancer forms in which CMV may play a central role. By studying medullablastomas, the most common form of childhood brain tumour, researchers at Karolinska Institutet have been able to show for the first time the presence of CMV in these tumours and that treatment for CMV can reduce tumour growth.

"We show in this study that CMV is found in 92 per cent of tumours from medullablastoma patients," says Professor Cecilia Söderberg-Nauclér. "We also show in experimental systems that we can inhibit the growth of these tumours with antiviral drugs, which opens up a new potential therapeutic approach to certain tumours in the future."

Earlier studies have shown that many forms of tumour also have a higher expression of the COX-2 enzyme, which is not found in normal tissue but which plays a key part in inflammations and the development of cancer. As regards tumours, it has previously been shown that for unknown reasons COX-2 is induced in tumour cells; a phenomenon often associated with poor prognoses. Further, the knowledge that COX-2 inhibitors reduce the risk of cancer has led to their use in clinical studies for cancer prevention. CMV in turn, greatly and specifically stimulates the synthesis of COX-2 and is thus a possible control signal for tumour growth. COX-2 inhibitors also reduce the production of CMV. The researchers now show in their paper, which is published in the Journal of Clinical Investigation, that tumour growth decreases when CMV is inhibited.

"Our experiments on mice show that tumour growth declines by around 40 per cent when antiviral drugs or COX-2 inhibitors are used separately, and by no less than 72 per cent when used in combination," says Professor Söderberg-Nauclér, adding that this effect is achieved without using chemotherapy.

Since both the drugs used in the study, an NSAID that inhibits CMV replication and inflammation, and the antiviral Valcyte (Valganciclovir) for CMV infection, have relatively good adverse effect profiles, the researchers now see immediate opportunities for studying their impact on different forms of tumour. Antiviral drugs are also selective and largely affect infected cells.

"These are very promising and exciting results," says Professor Söderberg-Nauclér. "The virus infection isn't cured by the treatment, nor is the tumour, but the virus in the tumour decreases, which affects its growth. This therefore presents a new approach to treating tumours and could henceforth be used as a possible complementary therapy.

Story Source:

The above story is reprinted (with editorial adaptations by ScienceDaily staff) from materials provided by Karolinska Institutet.

--------------------------------------------------------------------------------

Journal Reference:

Ninib Baryawno, Afsar Rahbar, Nina Wolmer-Solberg, Chato Taher, Jenny Odeberg, Anna Darabi, Zahidul Khan, Baldur Sveinbjörnsson, O.-M. Fuskevåg, Lova Segerström, Magnus Nordenskjöld, Peter Siesjö, Per Kogner, John Inge Johnsen, Cecilia Söderberg-Nauclér. Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target. Journal of Clinical Investigation, 2011; DOI: 10.1172/JCI57147







  Treatment of Common Virus Can Reduce Tumour Growth, Study Suggests  이성욱 2011/10/04 2325
726   tRNA 합성효소의 이중기능(dual function)에 대한 미스터리 해명  이성욱 2009/12/18 6329
725   Tufts report confirms domination of biotech products  이성욱 2013/11/19 1865
724   Tumours grow their own blood vessels  이성욱 2010/11/25 2308
723   Tunable Form of CRISPR Is an Efficient Regulator of Stem Cell Expression  이성욱 2016/03/14 718
722   Turning T-cells into Cancer Killers  이성욱 2011/08/12 2532
721   U of M researchers discover gene required to maintain male sex throughout life  이성욱 2011/07/25 2282
720   U. Iowa team investigates function of 'junk DNA' in human genes  이성욱 2011/03/04 2209
719   UCD stem cell research battles Huntington's disease  이성욱 2012/02/01 2511
718   UK Duo Generates Haploid Mouse Stem Cells  이성욱 2011/09/14 2416
717   Un-junking junk DNA  이성욱 2013/11/15 1855
716   Uncovering a Key Player in Metastasis  이성욱 2011/11/21 2572
715   Uncovering Functions of Circular RNAs  이성욱 2017/08/14 743
714   Understanding HIV Latency to Undo It  이성욱 2011/05/23 2454
713   Unexpected Find Opens Up New Front in Effort to Stop HIV  이성욱 2011/01/31 2118
712   UPDATE 1-Merck says FDA turns down Gardasil for older women  이성욱 2011/04/08 4384
711   UPDATE 1-Vertex drug promising in hep C patients with HIV  이성욱 2011/03/04 2615
710   UPDATE 2-Gilead experimental drug fights all forms of hep C: data  이성욱 2015/09/24 844
709   UPDATED: FDA ushers in a new era in cancer treatment with ‘historic’ CAR-T approval for Novartis  이성욱 2017/08/31 712
708   Urine predicts prostate cancer risk  이성욱 2011/08/08 2526

[이전 10개] [1]..[21][22][23][24][25][26][27] 28 [29][30]..[64] [다음 10개]
 

Copyright 1999-2022 Zeroboard / skin by ROBIN